When Chest Pain/ Shortness of Breath Strikes
Pneumonia
e.g., flu, COVID-19 or other viral infection
Heart disease
e.g., acute myocardial infraction, unstable angina, or acute heart failure
Clots
e.g., pulmonary embolism
Non-malignant conditions
e.g., anxiety or post strenuous exercise
Pneumonia
e.g., flu, COVID-19 or other viral infection
Non-malignant conditions
e.g., anxiety or post strenuous exercise
Heart diseases
e.g., acute myocardial infraction, unstable angina, or acute heart failure
Clots
e.g., pulmonary embolism
Should we drive to the ER immediately and lose a
night of sleep
or take a risk and wait until morning to call a physician?
Unnecessary ER Visits and Hospitalization due to Chest PainBreathlessness
> 3 billion
in annual
hospital
expenditures due to chest pain
>90%
of ER visits chest pain accounts for could be reduced
> 4 million
of emergency room visits per year
due to dyspnea
>80% of ER visits due to dyspnea does not require hospital admission
ER services
Cost up to 12 times as much as a regular physicuan's visit
Cost the heath system more than 32 billion each year
Our Solution
Our home testing solution provides an alternative scenario that may spare the sick patient a drive to the ER, long waits of at least 2-hours, duplicative testing and wildly inflated bills.
By utilizing a portable home reader, NanoPAL™ together with our ultra-sensitive immunosensor technology, SeraParma™ home tests help analyze multiple biomarker testing results and assist telehealth physicians in determining the crucial next steps for a sick patient.
Shifting the current healthcare expenditure from cure to prevention
On average, the annual total medical costs for heart failure care were estimated at $24,383 per patient, $22,528-32,345 per patient for acute coronary syndrome, and $15,000-40,000 per patient for pulmonary embolism. The majority of those costs were appropriated due to hospitalizations. With our home test solution, patients can test for the relevant biomarkers and communicate with their telehealth physicians, at less than 10% of the average annual total medical costs associated with these diseases.
SeraParma™ : An Accurate and Astute Technology Platform for Early Disease Diagnosis
High-accuracy Early Antibody Rapid Detection
The only 3-step rapid test that can detect IgM on the first day upon showing symptoms. All it takes is 3 simple steps, one drop of blood and 15 minutes
Innovative Nanoparticle Signal Amplification Technology
1,000 times more sensitive than rapid tests that are currently available, SeraParma™ can detect early infection(as early as the first day after symptom onset) with zero false negative
Clinical validation Shows 100% Sensitivity, 100% Specificity
100% agreement between PCR and SeraParma™ testing results from 241 samples
The Only High-specificity Rapid Test with Wash Buffer
The unique rapid test with wash buffer greatly increases specificity with zero false positive
